Pfizer ($PFE), GlaxoSmithKline ($GSK) and NovaDigm Therapeutics are each in search of a vaccine to put a stop to methicillin-resistant Staphylococcus aureus, known as MRSA, a staph infection that kills more people in the United States than skin cancer, Bloomberg reports.
Some of the biggest innovations likely to come to the medical device industry may come from enhancing some of the most basic products in the sector. A Brown University scientist and his team may have hit on something just along those lines, by coating catheters and endotracheal tubes with selenium nanoparticles to beat back bad bacteria.
NovaDigm Therapeutics is developing a vaccine that could work against both bacteria and fungi, and could even combat resistant bacteria such as MRSA. The company presented Phase I results at the 15th Annual Conference on Vaccine Research.
Sorrento Therapeutics a two-year, $600,000 grant from the National Institute of Allergy and Infectious Diseases to support the company's develoment of antibody therapeutics and vaccines for Staph